Skip to main content
x

Recent articles

Jefferies 2024 – Cargo tries again with an old idea

A CD22-directed Car that has had several owners will next year deliver its most important dataset.

Scancell’s dilemma delayed

The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.

No PRAME encore for Immatics

A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.

The markets stress over Nuvectis

NXP800 yields neither severe thrombocytopenia, nor any responses.

Merck & Co gets in on the bispecific act

For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.

ASH 2024 preview – more challenges to the BTK order

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

Most Popular